The question of whether they are variants of mixed hyperplastic adenomatous
polyp/ serrated adenomas requires further study, as pointed out by Yokoo.
CELEBREX(TM) (celecoxib capsules) has been approved to reduce the number of adenomatous
colorectal polyps in patients with familial adenomatous
polyposis (FAP) as an adjunct to usual care (endoscopic surveillance and surgery).
Despite recent suggestions to the contrary by some video capsule endoscopy (VCE) enthusiasts, push enteroscopy remains the preferred method for evaluation of patients with familial adenomatous
polyposis (FAP), based on the results of his prospective comparative study, said Dr.
FAP is a relatively rare hereditary condition characterized by the development of hundreds to thousands of adenomatous
polyps in the colon and rectum during adolescence and early adulthood.
The disorder requires careful management, because untreated familial adenomatous
polyposis (FAP) leads to colon cancer 100% of the time.
Eighty-five percent of colorectal cancers result from chromosomal instability, with acquired mutations progressively accumulating in the adenomatous
polyposis coli (APC) and p53 tumor suppressor genes, and in the k-ras oncogene.
In asymptomatic patients, what is the sensitivity and specificity of virtual CT colonoscopy for detecting adenomatous
polyps in asymptomatic adults?
Persons with less closely related relatives with colorectal cancer or adenomatous
polyps should be advised to have screening as average-risk patients.
endoscopic surveillance and surgery) for patients with familial adenomatous
polyposis (FAP) -- a rare and devastating hereditary disease that left untreated almost always leads to colorectal cancer.
polyps were deemed advanced neoplasias if they were at least 10 mm or had high-grade dysplasia, a prominent villous component, or a focus of malignancy.
Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) today overwhelmingly recommended approval of Celebrex(TM) (celecoxib capsules) as an adjunct to current standard of care for patients with familial adenomatous
polyposis (FAP) -- a rare and devastating genetic disease that usually leads to colorectal cancer.
Only 5% of patients had at least one adenomatous
polyp of 10 mm or greater in diameter (Gastroenterology 125:311-19, 2003).
Pursuing COX-2 Technology in Familial Adenomatous
polyposis or hereditary nonpolyposis colorectal cancer (every 2 years if aged 20-40, every year after age 40).
The company is seeking marketing approval of Aptosyn for the treatment of adenomatous
polyposis coli ("APC"), a rare disease that puts those afflicted at high risk of developing colon cancer.